POTENTIAL OPTIMISATION OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE

https://www.eahp.eu/25-4CPS-122

M. Llinares-Esquerdo[1], S. Martínez-Pérez[1], G. Miralles-Andreu[1], M. Pomares-Bernabeu[1], I.P. Jiménez-Pulido[1], A. Navarro Ruiz[1].
[1]Hospital General Universitario De Elche, Pharmacy, Elche, Spain.

BACKGROUND:

Ustekinumab in Crohn's disease (CD) Ustekinumab dosage:

→ 1st IV administration.

→ Followed by 90mg SC every 8 (q8W) or 12 weeks (q12W) depending on response to treatment (EMA product information).

PURPOSE:

Review the use of Ustekinumab in patients with CD in a third level hospital.

Identify those with sustained remission that are susceptible to optimization, evaluating the associated economic impact.

MATERIAL AND METHODS:

Descriptive cross-sectional study.

Patients included: adults with CD under active treatment with Ustekinumab in September-2019 and who were treated in the Hospital Outpatient Pharmacy.

VARIABLES COLLECTED:

→ Demographic: sex and age.

→ Pharmacotherapeutic: previous biological treatment, treatment time with Ustekinumab and dosage.

→ Clinical: response to treatment according to the prescriber. Classified based on the presence or absence of a sustained response (> 4 months of symptomatic stability with the same dosage schedule).

→ Economic: economic impact associated with the optimization of the administration interval in patients with sustained response was determined.

RESULTS:

90% men

48 years(18-75)

Average time in treatment 11months

No prior biological treatment: n=2

30 patients

Prior biological treatment:

Integrin α4β7-inhibitor drug n=8

1 anti-TNF n=15

2 anti-TNFn=3

Integrin α4β7-inhibitor drug and anti-TNF n=2



30% patients were identified in whom clinical stability was observed in the last 4 months.

Potential saving*:

75.000€
(13% of economic impact)
*estimated in the event that the recommendation to optimize treatment is followed in 100% of patients with sustained response.

DISCUSSION AND CONCLUSION:

The most commonly drug regimen for ustekinumab in CD is 90mg q8W. However,17% of the patients have required dosage intensification.
A significant number of the patients show clinical stability and could be candidates for a treatment optimization with a very close follow-up by the multidisciplinary team.The optimization could mean significant economic savings.

Acknowledgements: Thank you to my workmates

L04 - Immunosuppressive agents
4CPS-122